RMM
VC Fund
Gent, Belgium
RMM is a VC fund in Gent focused on Biotechnology and Medical Device. Rudi M. Mariën's investment vehicle.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries RMM invests in
BiotechnologyMedical DeviceHealth CareManufacturingHealth Diagnostics
Stages RMM invests in
Series BSeries CSeries DSeries EVenture - Series Unknown
Countries RMM invests in
BelgiumGermanySwitzerland
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Rudi M. Marien
|
|||
Investment Focus
Industry
- Biotechnology 2 (40%)
- Medical Device 2 (40%)
- Health Care 1 (20%)
- Manufacturing 1 (20%)
- Health Diagnostics 1 (20%)
Stage
- Series B 1 (20%)
- Series C 1 (20%)
- Series D 1 (20%)
- Series E 1 (20%)
- Venture - Series Unknown 1 (20%)
Country
- Belgium 1 (20%)
- Germany 1 (20%)
- Switzerland 1 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Rudi M. Marien
Founder, CEO
|
Founder, CEO | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
JenaValve Technology
|
JenaValve Technology, Inc. is a medical device company focused on the design, development, and commercialization of innovative transcatheter heart valve solutions for the treatment of patients suffering from heart valve disease. The Company’s Trilogy™ Heart Valve System is a transcatheter aortic valve replacement (“TAVR”) system designed to treatpatients with symptomatic, severe aortic regurgitation (“AR”) and aortic stenosis (“AS”) in high surgical risk patients. The Trilogy System received CE Mark approval in May 2021, providing European physicians, for the first time, a device with true dual-disease treatment capabilities.JenaValve received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) to facilitate the review of ALIGN-AR, a pivotal trial in the U.S., as part of its premarket approval (“PMA”) application for the Trilogy Heart Valve System for the treatment of symptomatic, severe aortic regurgitation (AR) in high surgical risk patients. If approved, Trilogy would become the first and only TAVR system in the U.S. to be indicated for the treatment of AR patients.JenaValve is headquartered in Irvine, California, with additional locations in Leeds, U.K., and Munich, Germany. Additional information is available at www.jenavalve.com. US: CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use. | $100M / Series C / Aug 31, 2022 | |
Antelope Dx
|
Antelope Dx is a company developing a palm-sized diagnostic device for home testing. | $10.7M / Series B / Sep 15, 2020 | |
|
JenaValve Technology
|
JenaValve Technology, Inc. is a medical device company focused on the design, development, and commercialization of innovative transcatheter heart valve solutions for the treatment of patients suffering from heart valve disease. The Company’s Trilogy™ Heart Valve System is a transcatheter aortic valve replacement (“TAVR”) system designed to treatpatients with symptomatic, severe aortic regurgitation (“AR”) and aortic stenosis (“AS”) in high surgical risk patients. The Trilogy System received CE Mark approval in May 2021, providing European physicians, for the first time, a device with true dual-disease treatment capabilities.JenaValve received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) to facilitate the review of ALIGN-AR, a pivotal trial in the U.S., as part of its premarket approval (“PMA”) application for the Trilogy Heart Valve System for the treatment of symptomatic, severe aortic regurgitation (AR) in high surgical risk patients. If approved, Trilogy would become the first and only TAVR system in the U.S. to be indicated for the treatment of AR patients.JenaValve is headquartered in Irvine, California, with additional locations in Leeds, U.K., and Munich, Germany. Additional information is available at www.jenavalve.com. US: CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use. | $50M / Venture - Series Unknown / Feb 05, 2020 | |
Biocartis Group NV
|
Biocartis SA, a molecular diagnostics company, develops diagnostics technology platform for multiplexed detection of bio-analytes. It focuses on integrated molecular and immunodiagnostics based on its proprietary micro-technology platform. The company develops and licenses a series of technologies to build a diagnostics platform for multiplexeddetection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. Its products are used for various applications, including analysis of bio-molecules associated with risks factors, early detection, staging, treatment selection, and monitoring of a disease. Biocartis SA was founded in 2007 and is based in Lausanne, Switzerland. | $32.9M / Series E / Nov 05, 2013 | |
|
Biocartis Group NV
|
Biocartis SA, a molecular diagnostics company, develops diagnostics technology platform for multiplexed detection of bio-analytes. It focuses on integrated molecular and immunodiagnostics based on its proprietary micro-technology platform. The company develops and licenses a series of technologies to build a diagnostics platform for multiplexeddetection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. Its products are used for various applications, including analysis of bio-molecules associated with risks factors, early detection, staging, treatment selection, and monitoring of a disease. Biocartis SA was founded in 2007 and is based in Lausanne, Switzerland. | $37.8M / Series D / Dec 12, 2012 |
Co-Investors
Bain Capital Life Sciences
2 deals together
Andera Partners
2 deals together
Gimv
2 deals together
Johnson & Johnson Development Corporation
2 deals together
PMV Tina Fund
2 deals together
Valiance Asset Management
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Health Care Investors
43,014 investors
Climate Investors
40,325 investors
Manufacturing Investors
24,696 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Device Investors
11,047 investors
Health Care VC Funds
32,370 investors
Climate VC Funds
33,091 investors
Manufacturing VC Funds
21,540 investors
FAQ
What does RMM invest in?
RMM invests primarily in Biotechnology, Medical Device and Health Care startups, most often at Series B and Series C stage. Most of the 5 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact RMM?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at RMM?
The team at RMM includes Rudi M. Marien (Founder, CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
